Transplantation Research Center, Samsung Biomedical Research Institute, Seoul, Korea.
Samsung Medical Center, Stem Cell & Regenerative Medicine Institute, Seoul, Korea.
Xenotransplantation. 2018 Jan;25(1). doi: 10.1111/xen.12342. Epub 2017 Nov 14.
Porcine islet xenotransplantation is considered an attractive alternative treatment for type 1 diabetes mellitus. However, it is largely limited because of initial rejection due to Instant Blood-Mediated Inflammatory Reaction (IBMIR), oxidative stress, and inflammatory responses. Recently, soluble tumor necrosis factor-ɑ receptor type I (sTNF-αR) and heme oxygenase (HO)-1 genes (HO-1/sTNF-αR) have been shown to improve the viability and functionality of porcine islets after transplantation.
In this study, genetically modified mesenchymal stem cells (MSCs) expressing the HO-1/sTNF-αR genes (HO-1/sTNF-αR-MSC) were developed using an adenoviral system, and porcine islet viability and function were confirmed by in vitro tests such as GSIS, AO/PI, and the ADP/ATP ratio after coculturing with HO-1/sTNF-αR-MSCs. Subsequently, isolated porcine islets were transplanted underneath the kidney capsule of diabetic humanized mice without MSCs, with MSCs or with HO-1/sTNF-αR-MSCs.
According to the results, the HO-1/sTNF-αR-MSC-treated group exhibited improved survival of porcine islets and could reverse hyperglycemia more than porcine islets not treated with MSCs or islets cotransplanted with MSCs. Moreover, the HO-1/sTNF-αR-MSC group maintained its morphological characteristics and the insulin secretion pattern of transplanted porcine islets similar to endogenous islets in immunocompetent humanized mice.
Our results suggest that HO-1/sTNF-αR-MSCs are efficient tools for porcine islet xenotransplantation, and this study may provide basic information for pre-clinical animal models and future clinical trials of porcine islet xenotransplantation.
猪胰岛异种移植被认为是治疗 1 型糖尿病的一种有吸引力的替代治疗方法。然而,由于最初的排斥反应,主要是由于即时血液介导的炎症反应(IBMIR)、氧化应激和炎症反应,其应用受到了很大的限制。最近,可溶性肿瘤坏死因子-α受体 I 型(sTNF-αR)和血红素加氧酶(HO)-1 基因(HO-1/sTNF-αR)已被证明可提高移植后猪胰岛的活力和功能。
在这项研究中,使用腺病毒系统开发了表达 HO-1/sTNF-αR 基因的基因修饰间充质干细胞(HO-1/sTNF-αR-MSC),并通过体外试验(如 GSIS、AO/PI 和 ADP/ATP 比)证实了猪胰岛的活力和功能在与 HO-1/sTNF-αR-MSC 共培养后。随后,将分离的猪胰岛在没有 MSC、MSC 或 HO-1/sTNF-αR-MSC 的情况下移植到糖尿病人源化小鼠的肾包膜下。
根据结果,HO-1/sTNF-αR-MSC 处理组猪胰岛的存活率提高,逆转高血糖的能力强于未用 MSC 处理的猪胰岛或与 MSC 共移植的猪胰岛。此外,HO-1/sTNF-αR-MSC 组维持了其形态特征和胰岛素分泌模式,类似于免疫活性人源化小鼠内源性胰岛。
我们的结果表明,HO-1/sTNF-αR-MSC 是猪胰岛异种移植的有效工具,本研究可为猪胰岛异种移植的临床前动物模型和未来临床试验提供基础信息。